4.7 Review

Recent advances in the study of (-)clausenamide: chemistry, biological activities and mechanism of action

期刊

ACTA PHARMACEUTICA SINICA B
卷 4, 期 6, 页码 417-423

出版社

INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2014.10.004

关键词

(-)Clausenamide; Enantiomers; Cognition; Alzheimer's disease pathology; Tau; High phosphorylation; Synaptic plasticity

向作者/读者索取更多资源

Clausenamide (clau) is one of seven novel compounds isolated from Clausena lansium (Lour) skeels. Clau is unusual in that it contains 4 chiral centers yielding 8 pairs of enantiomers. After identification of the configuration of these enantiomers, the synthesis of 16 enantiomers, including optically active clau and (+) and (-)clau was carried out. During this study, many stereochemical and synthetic difficulties were solved and the Baldwin principle was updated. Production scale is now sufficient to meet the needs of clinical practice. In a pharmacological study numerous models and indicators showed that (-)clau is the active enantiomer, while (+)clau is inactive and elicits greater toxicity than (-)clau. The principal pharmacological effects of (-)clau are to increase cognition, demonstrated in ten models of memory impairment, as well as to inhibit beta-amyloid (A beta) toxicity, blocking neurofibrillary tangle formation by inhibiting the phosphorylation of tau protein. This antidementia effect is characterized by increased synaptic plasticity both in efficacy and in structure and provides new support for the theory that synaptic loss is the main cause of dementia. (-)clau is considered to be a promising drug candidate for treatment of Alzheimer's disease and other neurodegenerative disorders. (C) 2014 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据